Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary Hyperparathyroidism - Overview
Secondary Hyperparathyroidism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Secondary Hyperparathyroidism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
Amgen Inc
Cinkate Corp
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tabe Pharma Corp
Novadiol Inc
OPKO Health Inc
Scohia Pharma Inc
Shaanxi Micot Technology Co Ltd
TaiRx Inc
Vidasym Inc
Secondary Hyperparathyroidism - Drug Profiles
calcifediol ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
cicalcet - Drug Profile
Product Description
Mechanism Of Action
CK-15 - Drug Profile
Product Description
Mechanism Of Action
CTA-091 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Dendocrin - Drug Profile
Product Description
Mechanism Of Action
etelcalcetide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
evocalcet - Drug Profile
Product Description
Mechanism Of Action
History of Events
MT-1013 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SCO-006 - Drug Profile
Product Description
Mechanism Of Action
SHR-6508 - Drug Profile
Product Description
Mechanism Of Action
VS-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Secondary Hyperparathyroidism - Dormant Projects
Secondary Hyperparathyroidism - Discontinued Products
Secondary Hyperparathyroidism - Product Development Milestones
Featured News & Press Releases
Jul 06, 2021: MICOT’s MT1013 project completed the enrollment of the first subject in Phase I clinical trials in the United States
Apr 09, 2021: MICOT’s third variety MT1013 was approved for clinical use in the United States
Dec 21, 2020: Launch of Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent in Japan
Jun 29, 2020: ONO receives manufacturing and marketing approval in Japan for Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent
Mar 25, 2020: OPKO Health reports interim results for two ongoing RAYALDEE studies
Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients
Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Cada
May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintence Dialysis in Japan
Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintence Dialysis in Japan
Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology
Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE
Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintence Dialysis Patients in Japan
Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Rel Division Chief Commercial Officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Secondary Hyperparathyroidism, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Secondary Hyperparathyroidism, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Secondary Hyperparathyroidism - Pipeline by Amgen Inc, 2022
Secondary Hyperparathyroidism - Pipeline by Cinkate Corp, 2022
Secondary Hyperparathyroidism - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Secondary Hyperparathyroidism - Pipeline by Novadiol Inc, 2022
Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, 2022
Secondary Hyperparathyroidism - Pipeline by Scohia Pharma Inc, 2022
Secondary Hyperparathyroidism - Pipeline by Shaanxi Micot Technology Co Ltd, 2022
Secondary Hyperparathyroidism - Pipeline by TaiRx Inc, 2022
Secondary Hyperparathyroidism - Pipeline by Vidasym Inc, 2022
Secondary Hyperparathyroidism - Dormant Projects, 2022
Secondary Hyperparathyroidism - Discontinued Products, 2022